BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

Corcept Therapeutics: One Drug Fading, One Just Born, and a Stock Priced for Neither

Moe Alsumidaie by Moe Alsumidaie
September 29, 2026
in Research Notes
0
75
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

For most of its life, Corcept Therapeutics was essentially a one-drug company. Korlym, its mifepristone pill for Cushing’s syndrome (a rare hormonal disorder where the body produces too much cortisol), built the whole business from scratch. Then, in early 2026, a second drug arrived. And almost simultaneously, generic competition cleared the runway to undercut the first. Two things that rarely happen at once, happening at once, is the story.

Before anything else

The 10-Q for the quarter ended June 30, 2026 shows Korlym still growing, a brand-new drug already generating real revenue, and full-year guidance raised sharply. The stock has more than tripled in six months, our data shows, pricing in a transition that has barely started. The open question is whether the new drug grows fast enough to replace what generics will eventually take.

The number that should not exist next to the other number

Korlym brought in $208.6 million in Q2 2026, up about 7% from the same quarter a year earlier, with record new prescriptions. In the same quarter, Corcept booked a net loss. A company setting prescription records and losing money in the same three months is not a contradiction you can ignore. The explanation is that Corcept spent heavily to launch its second drug, Lifyorli, approved in March 2026 for a form of ovarian cancer that stops responding to platinum-based chemotherapy. Launch costs front-load the income statement: the sales force is hired, the samples are shipped, the marketing runs, before the revenue catches up. That is the mechanical reason. Whether the revenue catches up fast enough is the whole question.

What Lifyorli’s first quarter actually says

Lifyorli (relacorilant) generated $47.6 million in its first full commercial quarter. For context, that is roughly what Korlym earns in three weeks. A new oncology drug at that level in quarter one is not a failure, but it is also not yet a replacement for a franchise doing roughly eight hundred million dollars a year. The math of the transition is simple to state and hard to execute: Lifyorli must compound its growth while Korlym’s generic erosion, expected to begin as early as late 2026 following a patent challenge in February 2026, subtracts from the other side of the ledger. The first few quarters of Lifyorli’s trajectory represent the most consequential data the company will produce for assessing the transition thesis.

BullScope TerminalCORT was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

The guidance revision as a signal

Management raised full-year 2026 revenue guidance to a range meaningfully above where it started the year, roughly a fifth higher at the midpoint than the original estimate. That is not a rounding adjustment. It implies the combined business is running well ahead of where Corcept itself expected at the start of the year. The company held $515.4 million in cash and equivalents as of March 31, 2026, enough to fund the launch spending without needing to raise money from outside investors, which matters because raising new money dilutes existing shareholders.

An 8-K filed September 23, 2026 also disclosed a planned leadership transition inside the Endocrinology division, effective October 1. The filing does not characterize it as a strategic pivot, but a division-level change at the exact moment Korlym faces its first generic threat is worth noting as a data point, not a verdict.

What the mood is paying for

The stock has risen more than 200% in six months, our data shows. That move compresses the math into a tight space. The trailing price-to-earnings ratio, the price a buyer pays for each dollar the company earned over the past year, sits far above this stock’s decade median, though the gap is partly an artifact: launch spending collapsed the earnings denominator, making the ratio look more extreme than the underlying business alone would justify. Still, the mood is clearly paying for a future where Lifyorli scales fast and Korlym’s decline is orderly. Filed numbers cannot yet confirm either assumption.

Reading the numbers

  • Korlym Q2 2026 revenue: $208.6 million. What it is: net sales of the mifepristone pill for Cushing’s syndrome. What it means here: the legacy franchise is still growing at 7% year-over-year, but faces generic entry as early as late 2026. Everyday terms: a shop doing $200 a week in sales, still growing, but a competitor is about to open next door.
  • Lifyorli Q2 2026 revenue: $47.6 million. What it is: first full commercial quarter for the new ovarian cancer drug. What it means here: a promising start, but roughly one-fifth of what Korlym earns in the same period. Everyday terms: a new branch office bringing in $47 while the flagship earns $208, in the same month.
  • Cash position (March 31, 2026): $515.4 million. What it is: liquid reserves on the balance sheet. What it means here: enough runway to absorb launch losses without selling new shares. Everyday terms: a household with eight months of expenses saved before a big career transition.
  • Full-year 2026 guidance: $1.1 billion to $1.2 billion. What it is: management’s own estimate of annual revenue. What it means here: raised sharply mid-year, signaling the combined business is tracking above internal expectations. Everyday terms: a contractor who quoted $950 in January and revised to $1,150 by July because the work came in faster than planned.
  • Trailing P/E: 128.6 times (decade median: 32.5 times). What it is: price paid per dollar of recent earnings. What it means here: the ratio is inflated by a temporary earnings trough from launch costs, not purely by speculative richness, but the stock is still priced for a very specific outcome. Everyday terms: paying $128 for a business that earned $1 last year, when the same business historically traded at $33 per dollar earned.

Sources

  • 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
  • 10-Q, quarter ended March 31, 2026 (SEC EDGAR)
  • Corcept Q2 2026 earnings release (BioSpace)
  • Zacks via TradingView: Q2 earnings and guidance raise
  • 8-K filed September 23, 2026 (StockTitan)
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read CORT’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Ligand Pharmaceuticals: Royalties Are Surging. The Stock Price Assumes They Never Stop.

by Moe Alsumidaie
November 6, 2026
0

Ligand spent most of the last decade shedding things. It spun off its antibody discovery unit in November 2022, sold assets, and narrowed toward a single idea: own...

Read moreDetails

Harrow: Revenue Doubles, Equity Nearly Vanishes, and the Stock Is Down by Half

by Moe Alsumidaie
November 5, 2026
0

The quick read Harrow's filed numbers show revenue growing at a pace most pharmaceutical companies never see, more than fivefold in five years. The 10-Q filed for the...

Read moreDetails

Adaptive Biotechnologies: The Company That Lost Money for Years Just Turned a Quarterly Profit, and the Stock Is Priced Like It Already Won

by Moe Alsumidaie
November 5, 2026
0

In one breath Adaptive Biotechnologies spent six straight years burning more cash than it earned, losing more than a dollar for every dollar of revenue as recently as...

Read moreDetails

Vericel: The Company That Finally Started Making Money Is Priced Like It Stopped

by Moe Alsumidaie
November 4, 2026
0

For most of its public life, Vericel lost money while growing fast. It sells two unusual things: living skin grafts for severe burn patients, and cartilage repair implants...

Read moreDetails

Xeris Biopharma: A Company That Just Turned Profitable Is Being Priced Like One That Always Was

by Moe Alsumidaie
November 4, 2026
0

Four years ago, Xeris Biopharma was losing more than two dollars for every dollar it brought in. Today, the 10-K for fiscal year 2025 shows the company crossed...

Read moreDetails
Next Post

Emergent BioSolutions: The Quarter That Beat the Forecast, and the Write-Down That Buried the Headline

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

The $200 Billion Bet: Alphabet Is Earning More Than Ever and Spending Faster Than Ever, and Both Are True at Once

August 6, 2026

One drug carries the revenue. The next one just got complicated.

September 2, 2026

Evidence Sheet: UnitedHealth Group (UNH)

November 4, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.